SFTPC and acute respiratory distress syndrome: Although early in vivo studies with this recombinant SP-Cff showed surfactant activities closely resembling those of native SP-C (Ikegami & Jobe, 1998), a recent clinical trial of patients with ARDS demonstrated that rSP-C surfactant neither decreased mortality nor improved patient oxygenation (Spragg et al., 2011).